A Phase II Study of Everolimus in Patients with FDG-PET Positive Intermediate Grade (Ki67 3-20%) Pancreatic Neuroendocrine Tumor Abstract #1158

Introduction: The RADIANT-3 trial showed Everolimus (EV), as active in patients (pts) with progressive well/intermediate grade PNETs. Intermediate/grade 2 (Ki67 3-20%) PNETs have variable biology. FDG-PET avidity is an independent negative factor for survival, consistent with aggressive disease biology- but such imaging is not used to select treatment as in the case of the RADIANT 3 trial.
Aim(s): Assess the activity of EV as first-line therapy in patients with FDG-avid intermediate/grade 2 PNETs.
Materials and methods: Eligible pts had newly diagnosed FDG-PET-avid grade 2 advanced PNET with measurable/ evaluable disease. ECOG PS 0-2. Adequate organ function. No prior systemic therapy for PNETs. Pts received EV 10mg po daily until disease progression. Pts were staged every 12 weeks with structural imaging/FDG and Gal-DOTA PET. Primary endpoint was PFS at 6 months. PET/structural imaging response rate, response duration, toxicity and QOL were also measured.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: ASSOC PROF Michael Michael
Keywords: everolimus, FDG-PET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour
Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#912 Serial 89Zr-bevacizumab PET in Patients with Neuroendocrine Tumors before and on Everolimus Treatment
Introduction: Everolimus increases PFS in patients with advanced NETs. Currently, no biomarkers are available for early selection of patients who will benefit from everolimus. Everolimus can reduce VEGF-A production by tumor cells.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Adrienne H Brouwers
#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET
Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Jerome Cros
Authors: Bucau M, Cros J, Raffenne J, Rebours V, ...
#871 Success with Lutetium-177 DOTATATE Therapy in Cushing’s Syndrome Caused by Functional Pancreatic Neuroendocrine Tumor (pNET) with Ectopic Adrenocorticotropic Hormone (ACTH) Secretion Refractory to Concomitant Everolimus, Pasireotide and Metyrapone
Introduction: We report a case of a 59-year-old female presenting with florid ACTH-dependent Cushing’s syndrome complicated by pulmonary cryptococcal infection.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Bryan A Chan
Authors: Chan B A, Wyld D, Burge M, Cuneo R, ...
#918 Hyperinsulinemic Hypoglycemia by an Ovarian Germ Cell Tumor
Introduction: A 76-yr-old woman was admitted to our department for recurrent hot flushes, sweating and dizziness associated with fasting hypoglycemia. Physical examination revealed abdominal obesity and ascites.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Marialberta Battocchio
Keywords: ovary, insulin, SSA, everolimus